2. Inflammation/Immunology

Inflammation/Immunology

Inflammation/Immunology

Related Products

PDF 93.1 MB

The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-108432
    BMS-741672 1004757-96-3 98%
    BMS-741672 is a selective and orally active CCR2 antagonist with an IC50 of 1.1 nM. BMS-741672 shows >700-fold selective for CCR2 than CCR5.
    BMS-741672
  • HY-108483
    RP 67580 135911-02-3 98%
    RP 67580 is a non-peptide antagonist of substance P (SP), competitively inhibits the binding of [3H]SP to neurokinin receptor 1 (NK1 receptor) in rat brain membranes with a Ki value of 4.16 nM. RP 67580 is a specific antagonist of NK1 receptors and can be used in the research of pain and neurogenic inflammation.
    RP 67580
  • HY-108492
    TC-SP 14 1257093-40-5 98%
    TC-SP 14 (compound 14) is an orally active and potent S1P1 agonist (EC50 = 0.042 μM) with minimal activity at S1P3 (EC50 = 3.47 μM). TC-SP 14 significantly reduces blood lymphocyte counts and attenuates a delayed type hypersensitivity (DTH) response to antigen challenge.
    TC-SP 14
  • HY-108524
    LG101506 331248-11-4 98%
    LG101506 is a selective and orally active RXR modulator with a Ki of 2.7 nM for RXRα. LG101506 can be used for the research of type 2 diabetes and cancer.
    LG101506
  • HY-108534
    PMX464 485842-97-5 98%
    PMX464 (AW 464), a thiol-reactive quinol, is the inhibitor of thioredoxin-thioredoxin reductase (Trx/TrxR) system. PMX464 can inhibit NF-κB-mediated proinflammatory activation of human type II alveolar epithelial cells.
    PMX464
  • HY-108538
    Ethacrynic acid D5 1330052-59-9 98%
    Ethacrynic acid D5 is a deuterium labeled Ethacrynic acid. Ethacrynic acid is a diuretic. Ethacrynic acid is an inhibitor of glutathione S-transferases (GSTs). Ethacrynic acid is a potent inhibitor of NF-kB-signaling pathway, and also modulates leukotriene formation. Ethacrynic acid also inhibits L-type voltage-dependent and store-operated calcium channel, leading to relaxation of airway smooth muscle (ASM) cells. Ethacrynic acid has anti-inflammatory properties that reduces the retinoid-induced ear edema in mice.
    Ethacrynic acid D5
  • HY-108548
    Rp-8-Br-PET-cGMPS sodium 185246-32-6 98%
    Rp-8-Br-PET-cGMPS sodium (Rp-8-Bromo-PET-cGMPS) is an analog of cyclic GMP (cGMP). It is a cell permeable, competitive, and reversible inhibitor of cGMP-dependent protein kinases (cGKs) that blocks activation of cGKI and cGKII by cGMP (Kis=35 and 30 nM). It less potently inhibits protein kinase A (Ki=11 μM) and cGMP-induced activation of cyclic nucleotide-gated channels (IC50=25 μM). In the absence of cGMP stimulation, Rp-8-bromo-PET-cGMPS can act as a partial agonist of cGKI (Ki=1 μM). Rp-8-bromo-PET-cGMPS is resistant to hydrolysis by phosphodiesterase 11.
    Rp-8-Br-PET-cGMPS sodium
  • HY-108601
    (S)-Ro 32-0432 free base 151342-35-7 98%
    (S)-Ro 32-0432 free base is a potent, selective, ATP-competitive and orally active PKC inhibitor. The IC50 values of (S)-Ro 32-0432 free base for PKCα, PKCβI, PKCβII, PKCγ and PKCε are 9.3 nM, 28 nM, 30 nM, 36.5 nM and 108.3 nM, respectively. (S)-Ro 32-0432 free base is also a selective G protein-coupled receptor kinase 5 (GRK5) inhibitor. (S)-Ro 32-0432 free base prevents T-cell activation and has the potential for chronic inflammatory and autoimmune diseases research.
    (S)-Ro 32-0432 free base
  • HY-108620
    CDP-840 162542-90-7 98%
    CDP-840 (GR259653X) is a potent, selective and orally active phosphodiesterase IV (PDE IV) inhibitor. CDP-840 inhibits antigen-induced early and late phase bronchoconstriction in conscious squirrel monkeys.
    CDP-840
  • HY-108622
    Mesopram 189940-24-7 98.80%
    Mesopram (Daxalipram) is an orally active phosphodiesterase (PDE) 4 inhibitor. Mesopram can be used for autoimmune disease research.
    Mesopram
  • HY-108641
    SKF-86002 dihydrochloride 116339-68-5 98%
    SKF-86002 dihydrochloride is an orally active p38 MAPK inhibitor, with anti-inflammatory, anti-arthritic and analgesic activities. SKF-86002 dihydrochloride inhibits lipopolysaccharide (LPS)-stimulate human monocyte IL-1 and TNF-α production (IC50 = 1 μM). SKF-86002 dihydrochloride inhibits lipoxygenase- and cyclooxygenase-mediated metabolism of arachidonic acid.
    SKF-86002 dihydrochloride
  • HY-108644
    SB 706504 911110-38-8 98%
    SB 706504 is a potent p38 MAPK inhibitor that inhibits Lipopolysaccharides (HY-D1056)-stimulated inflammatory gene expression in macrophages in chronic obstructive pulmonary disease (COPD).
    SB 706504
  • HY-108842
    Peginterferon alfa-2b 215647-85-1 ≥99.0%
    Peginterferon alfa-2b (PegIFN a-2b) is an immunomodulator. Peginterferon alfa-2b is a recombinant alfa-2b interferon covalently linked PEG. Peginterferon alfa-2b in decreasing viral DNA in HIV. Peginterferon alfa-2b can be used in research of melanoma and hepatitis C.
    Peginterferon alfa-2b
  • HY-108953
    (S)-Quinolactacine A 319917-25-4 98%
    (S)-Quinolactacine A is a quinolone inhibitor that targets TNF production.
    (S)-Quinolactacine A
  • HY-108960
    PPADS 149017-66-3 98%
    PPADS is a P2 receptor antagonist, with IC50s of 68 nM (P2X1) and 214 nM (P2X3). PPADS acts as an ATP (nucleotide) mimetic and competes with ATP for its binding site on P2 receptors. PPADS is also a reversible competitive antagonist of the NAADP receptor. PPADS reverses nociceptive hypersensitivity and reduces the increased NO/NOS system and IL-1β in both peripheral and central steps of nervous system.
    PPADS
  • HY-109692
    GPR120 Agonist 5 1079821-35-4 98%
    GPR120 Agonist 5 (compound 12) is an agonist targeting GPR120 (EC50=1.2 μM). GPR120 Agonist 5 promotes the release of glucagon-like 1 (GLP-1) by binding to the GPR120 receptor, which in turn binds to its receptors on pancreatic beta cells, increasing insulin secretion and thereby lowering blood sugar levels. GPR120 Agonist 5 also helps reduce chronic low-grade inflammation, which plays an important role in the pathogenesis of obesity, insulin resistance, and type 2 diabetes. GPR120 Agonist 5 can be used to investigate the mechanism of action of GPR120 in metabolic and inflammatory diseases.
    GPR120 Agonist 5
  • HY-109718
    ATL-801 1000005-71-9 98%
    ATL-801, an A2B receptor selective antagonist, ameliorates murine colitis.
    ATL-801
  • HY-10978S
    Crisaborole-d4 2268785-42-6 98.8%
    Crisaborole-d4 is deuterium labeled Crisaborole. Crisaborole (AN-2728) is a potent inhibitor of PDE4 and cytokine release; inhibit PDE4 with an IC50 of 0.49 μM.
    Crisaborole-d4
  • HY-109854
    (S)-Lisofylline 100324-80-9 99.89%
    (S)-Lisofylline ((S)-Lisophylline)) is a kind of lisofline (LSF) enantiomer with optical activity. (S)-Lisofylline can interconversion with pentoxifylline.
    (S)-Lisofylline
  • HY-110022
    GW1929 hydrochloride 1217466-21-1 98%
    GW1929 hydrochloride is an orally active peroxisome proliferator-activated receptor-γ (PPARγ) agonist with a pKi of 8.84 for human PPAR-γ, and pEC50s of 8.56 and 8.27 for human PPAR-γ and murine PPAR-γ, respectively. GW1929 hydrochloride has antidiabetic efficacy and neuroprotective potential. GW1929 hydrochloride suppresses neuronal apoptosis and shows anti-inflammatory potential.
    GW1929 hydrochloride
Cat. No. Product Name / Synonyms Application Reactivity